Needham Reiterates Buy on Pacira BioSciences, Maintains $43 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger reiterates a Buy rating on Pacira BioSciences (NASDAQ:PCRX) and maintains a $43 price target.
July 31, 2024 | 9:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger reiterates a Buy rating on Pacira BioSciences and maintains a $43 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $43 price target by a reputable analyst suggests a positive outlook for Pacira BioSciences. This could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100